Dott. Marco Ferrone

Il Dott. Marco Ferrone si è laureato in Medicina e Chirurgia presso l'Università degli Studi di Napoli Federico II. Sempre presso questa Università, si è specializzato in cardiologia, frequentando il Laboratorio di Emodinamica "Massimo Chiariello" sotto la guida del Prof. Giovanni Esposito acquisendo esperienza in interventistica coronarica, strutturale e periferica.

Pubblicazioni, ricerca, esperienze professionali

Esperienze professionali del Dott. Marco Ferrone

• Dal 2017 al 2019 presso lo Skirball Center della "Cardiovascular Research Foundation - CRF" di New York, Stati Uniti, sotto la guida del Prof. Juan Granada, studiando nuovi dispositivi per il trattamento percutaneo dell’insufficienza mitralica e della cardiopatia strutturale;
• Dal 2019 cardiologo interventista presso la Clinica Montevergine di Mercogliano (AV).

Queste le pubblicazioni del Dott. Marco Ferrone

• “Endovascular treatment of carotid artery stenosis: evidences from randomized controlled trials and actual indications” Monaldi Archives for Chest Disease, Cardiac Series - volume 76, 4 – 2011 Dec;
• “Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management” Current Vascular Pharmacology, 2012 May;
• “The role of atherectomy in the treatment of lower extremity peripheral artery disease” BMC Surgery, 2012 May;
• “Abdominal Aortic Aneurysm in patients affected by intermittent claudication: prevalence and clinical predictors” BMC surgery, 2012 May;
• “Endovascular Treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication” BMC surgery, 2012 May;
• “Ankle/Brachial Index to everyone” BMC Surgery, 2012 Nov;
• “Use of statins in lower extremity artery disease: a review” BMC surgery, 2012 Nov;
• “Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation” Apoptosis. 2013 Oct;
• “Percutaneous Coronary Intervention in a Patient with Acute Thrombosis of Saphenous Vein Graft and Patent Native Coronary Artery: Which is the Vessel to Approach?” AIMS Medical Science. 2015 Sept;
• “Determinants of myocardial mechanics in top-level endurance athletes: three-dimensional speckle tracking evaluation.” Eur Heart J Cardiovasc Imaging. 2016 Jun;
• “Abluminal biodegradable polymer-based Biolimus A9-eluting stent for the treatment of infrapopliteal arteries in critical limb ischemia: Long-term follow-up.” Int J Cardiol. 2016 Jan;
• “Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study” Cardiovascular Diabetology 2017 Jan;
• “Translational Research: The Cornerstone for Medical Technology Advancement.” Toxicol Pathol. 2019 Apr;
• “Current concepts regarding drug dosing for peripheral stents” J Cardiovasc Surg. 2019 May;
• “Long-term performance and biocompatibility of a novel bioresorbable scaffold for peripheral arteries: A three-year pilot study in Yucatán miniswine” Catheterization Cardiovascular intervention. February 2020;
• “Impact of Coronary Atherosclerosis on Bioresorbable Vascular Scaffold Resorption and Vessel Wall Integration” JACC: Basic to translational science. June 2020;
• “First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study” International Journal of Cardiology. August 2020;
• “First-in-human evaluation of the novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial.” Eurointervention. March 2020;
• “Complete revascularization in acute and chronic coronary Syndrome” Cardiology clinics. November 2020;
• “Impact of chronic kidney disease on platlet aggregation in patients with acute coronary syndrome” Journal of Cardiovasc Medicine. September 2020;
• “Downstream Paclitaxel Released Following Drug-Coated Balloon Inflation and Distal Limb Wound Healing in Swine” JACC: Basic to translational science. May 2021;
• "RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-months Imaging and 2-Year Clinical Results." Circulation Cardiovascular Intervention. May 2021;
• “Partial closure with a self-made fenestrated device of secundum atrial septal defect with severe pulmonary artery hypertension in adults.” Journal Geriatric Cardiology. June 2021;
• “Three-years outcome of directional atherectomy and anti-restenotic therapy (DAART) for the 3 treatment of common femoral artery steno-occlusive lesions.” Catheterization cardiovascular intervention. March 2022

Attività Accademica

Nel 2022 ha conseguito il dottorato di ricerca internazionale "Cardiovascular Pathophysiology & Therapeutics"

Perfezionato in

Cardiopatia ischemica

Patologie valvolari

Interventistica coronarica

Interventistica strutturale

Interventistica periferica

Lingue parlate

Italiano

Inglese